Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:06:15.714Z.
Calculation as of: 2026-10-06T15:06:15.714Z.
Quote observation: 2026-10-06T15:04:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 781bf18d5b555faf6525e3bbfdfcc877af608ad86c98afd042bd19dc8220ce7c
PE RATIO
N/A
Market Cap
$155.86M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. (CRDL) | $153.31M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $152.34M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.52M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $154.07M | N/A | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $154.91M | N/A | 4.03 | 4.03 | 14.59 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $150.59M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $154.72M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $155.86M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $156.63M | N/A | 65.68 | 52.50 | 80.75 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
